Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity

Cancer Immunology, Immunotherapy

Volumn 53, Issue 4, 2004, Pages 315-322

  Kim, Kwang Woon ^a,d   Kim, Sun Hee ^a   Jang, Jung Hee ^a   Lee, Eun Yup ^a   Park, Soon Won ^a   Um, Jee Hyun ^a   Lee, Yun Jung ^a   Lee, Chang Hun ^a   Yoon, Sik ^a   Seo, Su Yeong ^b   Jeong, Min Ho ^b   Lee, Seong Tae ^c   Chung, Byung Seon ^a   Kang, Chi Dug ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Sunchon National University   (South Korea)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Dendritic cells; Electroporation; Soluble antigens

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ELECTROPORATION; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNIZATION; LUNG CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; BONE MARROW CELLS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 12144287300     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0448-x     Document Type: Article

References (44)

1. Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P (1996) Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26:2595
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767
3. Brossart P, Wirths S, Brugger W, Kanz L (2001) Dendritic cells in cancer vaccines. Exp Hematol 29:1247
4. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283
5. De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K (1999) Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162:144
6. Delamarre L, Holcombe H, Mellman I (2003) Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 198:111
7. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM (1996) Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157:541
8. Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM (1997) Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol 158:3090
9. Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482
10. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605
11. Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245
12. Gehl J (2003) Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 177:437
13. Hui SW (2002) The application of electroporation to transfect hematopoietic cells and to deliver drugs and vaccines transcutaneously for cancer treatment. Technol Cancer Res Treat 1:373
14. Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589
15. Kloetzel PM (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179
16. Lambert H, Pankov R, Gauthier J, Hancock R (1990) Electroporation- mediated uptake of proteins into mammalian cells. Biochem Cell Biol 68:729
17. Lambert LA, Gibson GR, Maloney M, Barth RJ Jr (2001) Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 24:232
18. Li Y, Ke Y, Gottlieb PD, Kapp JA (1994) Delivery of exogenous antigen into the major histoconipatibility complex class I and class II pathways by electroporation. J Leukoc Biol 56:616
19. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297
20. McIlroy D, Gregoire M (2003) Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother (in press)
21. Mir LM, Banoun H, Paoletti C (1988) Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 175:15
22. Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673
23. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C (1997) Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27:280
24. Nouri-Shirazi M, Banchereau J, Fay J, Palucka K (2000) Dendritic cell based tumor vaccines. Immunol Lett 74:5
25. O'Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689
26. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317
27. Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918
28. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S (1999) Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371
29. Reid DC (2001) Dendritic cells and immunotherapy for malignant disease. Br J Haematol 112:874
30. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG (2002) Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 86:1529
31. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3
32. Rescigno M, Citterio S, Thery C, Rittig M, Medaglini D, Pozzi G, Amigorena S, Ricciardi-Castagnoli P (1998) Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A 95:5229
33. Rock KL, Benacerraf B (1983) Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers: evidence of specific competition for accessory cell antigen presentation. J Exp Med 157:1618
34. Rock KL, Rothstein L, Gamble S (1990) Generation of class I MHC-restricted T-T hybridomas. J Immunol 145:804
35. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1:362
36. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281
37. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467
38. Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J Exp Med 182:389
39. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213
40. Tarte K, Klein B (1999) Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13:653
41. Thery C, Amigorena S (2001) The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 13:45
42. White J, Haskins KM, Marrack P, Kappler J (1983) Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies. J Immunol 130:1033
43. Yewdell JW, Norbury CC, Bennink JR (1999) Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 73:1
44. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87